Varda's Vision: Space Manufacturing and the Quest for Cost-Effective Space Exploration
Varda Space Industries, led by CEO Will Bruey, is revolutionizing the space industry by proving that space manufacturing is not just a futuristic concept but a viable reality. Bruey envisions a future where space manufacturing becomes commonplace, and the process is made so efficient that it becomes 'boring.'
The company's journey began with a bold idea: manufacturing pharmaceuticals in space to create drugs with superior stability, purity, and shelf life. This concept is not entirely new, as companies like Bristol Myers Squibb and Merck have been conducting pharmaceutical crystallization experiments on the International Space Station for years. However, Varda aims to make this process commercial and scalable.
The 'Seven Domino' Theory
Bruey introduces the 'seven domino theory' to illustrate Varda's unique business model. The first domino is reusable rockets, which Varda has already achieved. The second domino is manufacturing drugs in orbit and returning them to Earth. The third, and most significant, is getting a drug into clinical trials, which requires perpetual launches.
This is where Varda's model diverges from traditional space companies. While satellite companies treat launches as a one-time capital investment, Varda's business model relies on continuous manufacturing runs and launches. Each drug formulation requires multiple launches, and the demand for drugs increases with success, creating a predictable and scalable demand for launch providers.
Overcoming Regulatory Hurdles
Varda's path to success was not without challenges. The company faced a near-death experience when its W-1 capsule remained stranded in orbit for six months due to regulatory approval issues. The Utah Test and Training Range, where Varda wanted to land, was primarily used for military purposes, and the company had to navigate complex approval processes.
Bruey's determination to push the boundaries of regulation led to a breakthrough. Varda successfully landed W-1 at the Utah Test and Training Range, becoming the first commercial spacecraft to land on a military test range and the first to land on U.S. soil under the FAA's Part 450 licensing framework.
Expanding Horizons: Hypersonic Testing
Varda's expertise in reentry at high speeds has led to a secondary business: hypersonic testing. The company's W-1 capsules can reach Mach 25 during reentry, providing a unique environment for testing materials, sensors, and equipment in extreme conditions. This capability is highly valuable to defense agencies, offering a safer and more cost-effective alternative to traditional test flights.
Investor Confidence and Future Prospects
Varda's innovative approach has attracted significant investor interest. The company raised $329 million in its Series C round, with funds allocated for expanding its pharmaceutical lab and hiring experts in structural biology and crystallization science. Bruey's vision of a future where space manufacturing becomes commonplace and cost-effective is gaining traction, and Varda is well-positioned to play a pivotal role in this transformative journey.
